Aeolus Pharmaceuticals Announces Second Quarter Fiscal Year 2008 Financial Results
LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS) announced today financial results for the three months ended March 31, 2008. The Company reported a net loss of 697,000, or 0.02 per share, compared to a loss of 544,000, or 0.02 per share, for the three months ended March 31, 2007, an increase of 28%.
“Our research and development programs for AEOL 10150 continue to progress well, with promising data from studies testing the compound as a protective agent against mustard gas exposure for the skin and lungs. We also have completed protocols and are ready to initiate mouse and primate studies of AEOL 10150 as a protective agent against radiation exposure in the lung,” stated John L. McManus, President and Chief Executive Officer. “Additionally, a second study of AEOL 11207 has been completed in Parkinson’s disease, and we expect to receive the results shortly.”
Read More »